Document:

EX-10.1

 Exhibit 10.1 

CONFIDENTIAL 

AMENDMENT TO SHAREHOLDERS AND REGISTRATION RIGHTS AGREEMENTS 

This amendment agreement (this “Amendment”), dated as of May 5, 2016, amends each of (i) that certain shareholders
agreement, dated as of May 18, 2015 (the “Shareholders Agreement”) and (ii) that certain registration rights agreement, dated as of May 18, 2015 (the “Registration Rights Agreement”), in each case by
and among TPG Sky L.P., TPG Sky Co-Invest L.P., TPG Biotechnology Partners IV L.P. (collectively, the “Shareholders”) and Endo International plc (“Parent”). 

WHEREAS, each of the Shareholders and Parent desire to amend the Shareholders Agreement and the Registration Rights Agreement to reflect
modifications to the rights and obligations set forth in such agreements relating to (x) the permission of the Shareholders to acquire certain additional ordinary shares, nominal value $0.0001 per share, of Parent (the “Ordinary
Shares”) and (y) the appointment to the board of directors (“Board”) of Parent of Todd B. Sisitsky, who is a partner of an affiliate of the Shareholders (“Sisitsky”); 

NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Shareholders
Agreement Amendments. The Shareholders Agreement is hereby amended as follows: 
 (a) Section 1.1 of the Shareholders Agreement is
hereby amended to add the following additional words to the end of the definition of the term “Registration Rights Agreement”: “, as amended.” 

(b) Section 3.1(a) of the Shareholders Agreement is hereby amended to insert at the beginning thereof the words “Subject to
Section 3.1(b) hereof,”. 
 (c) Section 3.1 of the Shareholders Agreement is hereby amended to add the following at the end
thereof as a new Section 3.1(b): “Notwithstanding anything to the contrary contained herein, the Shareholders may make Permitted Acquisitions. “Permitted Acquisitions” shall mean the acquisition by the Shareholders or
their respective Affiliates of Ordinary Shares of Parent solely by means of market purchases (whether related or unrelated) on the NASDAQ, Toronto Stock Exchange, or any other national stock exchange on which Parent’s Ordinary Shares may at
such time be listed and quoted, which market purchases: 
 (i) shall have commenced no earlier than the date on which the
waiting period applicable to such acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, shall have expired or been earlier terminated; 

(ii) shall have been completed no later than December 31, 2016; 

(iii) shall, in the aggregate, be for consideration of no more than $250,000,000; 

 (iv) shall be effected solely during periods of time during which, pursuant to
Parent’s then existing trading policy applicable to its directors and officers, Parent’s directors and officers are permitted to sell, purchase or otherwise trade securities of Parent without being subject to any applicable blackout
periods or other similar trading restrictions; and 
 (v) shall, involve an amount of Ordinary Shares, which, in the
aggregate, when taken together with the other Ordinary Shares of Parent beneficially owned by the Shareholders and their respective Affiliates, comprise less than 10% of the total Ordinary Shares of Parent outstanding on the date thereof.” 

(d) Section 3.1 of the Shareholders Agreement is hereby amended to add the following at the end thereof as a new Section 3.1(c):
“Each of the Shareholders acknowledges that it and its Affiliates, employees, attorneys, independent contractors designated as senior advisors, directors and officers may have access to material, non-public information of Parent, and it is
aware (and will so advise its Affiliates, employees, attorneys, independent contractors designated as senior advisors, directors and officers who are informed as to the matters which are subject to this Amendment and who receive confidential
information) that applicable securities laws, including United States federal and state securities laws, generally prohibit any person who has material, non-public information concerning a publicly-traded company from purchasing or selling any
securities of such company or from communicating such information to any other person or entity under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. Each receiving party agrees
that it will not, and will direct its Affiliates, employees, attorneys, independent contractors designated as senior advisors, directors and officers who have received confidential information not to, use or permit any third party to use any
confidential information in contravention of the United States federal and state securities laws, including the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.” 

(e) The Shareholders Agreement is hereby amended to add the following as a new Section 3.4: “Section 3.4. Director Conduct.
For the avoidance of doubt, without limiting any obligations of the Shareholders or any of their respective Affiliates (other than Sisitsky), Parent acknowledges that in no event shall any action taken by Sisitsky, in his capacity as a director of
Parent, to the extent consistent with the performance of his duties as a member of the Board of Parent constitute a breach of this Agreement.” 

(f) The Shareholders Agreement is hereby amended to add the following as a new Section 3.5: “Section 3.5 Public Announcement.

 (a) Parent shall file promptly a Form 8-K (the “Form 8-K”) reporting entry into this Amendment and appending or incorporating by
reference this Amendment as an exhibit thereto. 
 (b) The Shareholders shall promptly prepare and file a beneficial ownership report on Schedule 13D (the
“Schedule 13D”) with respect to Parent, reporting the entry into this agreement and amending the disclosure on the Shareholders’ beneficial ownership report on Schedule 13G with respect to Parent filed on October 2, 2015.

  
 2 

 (c) The parties shall cooperate in preparing a summary description of this Amendment for use in both
Parent’s Form 8-K and the Shareholders’ Schedule 13D. The Company shall provide the Shareholders with reasonably opportunity to review and comment upon Parent’s Form 8-K prior to filing, and shall consider in good faith any
changes proposed by the Shareholders. The Shareholders shall provide Parent with reasonable opportunity to review and comment upon the Schedule 13D prior to filing, and shall consider in good faith any changes proposed by Parent. 

(d) The Parent shall promptly issue a press release to be mutually agreed with the Shareholders in connection with this Amendment. 

(e) The Shareholders shall not, and the Shareholders shall cause their respective Affiliates not to, (i) issue a press release in connection with this
Amendment or (ii) except as contemplated by Section 3.5(c), otherwise make any public statement, disclosure or announcement with respect to this Amendment, other than as mutually agreed to by Parent and the Shareholders.” 

(g) The Shareholders Agreement is hereby amended to add the following as a new Section 3.6: “Section 3.6 Freedom to Pursue
Opportunities. Notwithstanding anything to the contrary herein, the parties expressly acknowledge and agree that: (a) each Shareholder, Representative of a Shareholder and Affiliate of a Shareholder, including any director of Parent that is
a Representative or Affiliate of a Shareholder or employed by a Representative or Affiliate of a Shareholder (each, a “Shareholder Party”), has the right to, (i) directly or indirectly engage in the same or similar business
activities or lines of business as Parent or any of its Subsidiaries, including those deemed to be competing with the Parent or any of its Subsidiaries, or (ii) directly or indirectly do business with any client, customer or supplier of Parent
or any of its Subsidiaries; and (b) in the event that any Shareholder Party is a director of Parent or any of its Subsidiaries and acquires knowledge of a potential transaction or matter that may be a corporate opportunity for Parent or any of
its Subsidiaries solely as a result of such Shareholder Party’s position on the Board, such Shareholder Party may not direct such corporate opportunity to any other Shareholder Party; provided that, other than as set forth in the preceding
clause, no Shareholder Party shall have any other obligation to Parent or any of its Subsidiaries with respect to any corporate opportunity. In the event of any conflict between this Section 3.6 and any other agreement or policy relating to
Parent or any of its Subsidiaries, this Section 3.6 shall control.” 
 (h) The Shareholders Agreement is hereby amended to add the
following additional words to the end of Section 5.9: “; provided, that each Shareholder Party shall be a third-party beneficiary for purposes of Section 3.6 of this Agreement.” 

2. Registration Rights Agreement Amendment. The Registration Rights Agreement is hereby amended as follows: 

(a) Section 1 of the Registration Rights Agreement is hereby amended to delete in its entirety clause (iii) of the definition of the
term “Registrable Securities” and replace it with the following new words: “(iii) such holder is able to immediately sell such securities under Rule 144 without any restrictions on transfer (including without application of paragraphs
(c), (d), (e), (f) and (h) of Rule 144), as reasonably determined by the Holder; or (iv) such Shares have ceased to be outstanding.” 

  
 3 

 (b) Section 1 of the Registration Rights Agreement is hereby amended to add the following
additional words to the end of the definition of the term “Registrable Securities”: “Notwithstanding anything to the contrary herein, but subject to the proviso in the foregoing sentence, any Shares acquired pursuant to a Permitted
Acquisition (as defined in the Shareholders Agreement) shall be deemed to be Registrable Securities.” 
 (c) Section 1 of the
Registration Rights Agreement is hereby amended to add the following additional words to the end of the definition of the term “Shareholders Agreement”: “, as amended.” 

(d) Section 7(b) of the Registration Rights Agreement is hereby amended to replace the word “earlier” with the word
“later”. 
 3. No Other Waiver or Amendment. Except as expressly contemplated by Sections 1 and 2 above, all provisions of
the Shareholders Agreement and the Registration Rights Agreement remain in full force and effect, on the terms and subject to the conditions set forth therein. This Agreement does not constitute, directly or indirectly, an amendment or waiver of any
provision of the Shareholders Agreement or the Registration Rights Agreement, or any other right, remedy, power or privilege of any party to the Shareholders Agreement or the Registration Rights Agreement, except to the extent expressly set forth
herein. 
 4. Primacy. In the event of any conflict between this Amendment (or any portion thereof) and the Shareholders Agreement,
the Registration Rights Agreement or any other agreement, the terms of this Amendment shall prevail. 
 5. Miscellaneous. Except as
set forth in Section 1(i) of this Amendment, Articles I and V of the Shareholders Agreement shall apply to this Amendment, mutatis mutandis. 

[Signature Pages Follow]  

  
 4 

 IN WITNESS WHEREOF, each of the parties hereto has executed this Amendment, or caused the same to
be executed by its duly authorized representative, as of the date first above written. 
  

			
	ENDO INTERNATIONAL PLC
		
	By:	 	/s/ Rajiv De Silva
		 	Name: Rajiv De Silva
		 	Title:   President and CEO

 [Signature Page to Amendment Agreement] 

 
			
	TPG SKY L.P.
		
	By:	 	TPG Advisors VI, Inc., its general partner
		
	By:	 	/s/ Clive Bode
		 	Name: Clive Bode
		 	Title:   Vice President
	
	TPG SKY CO-INVEST L.P.
		
	By:	 	TPG Advisors VI, Inc., its general partner
		
	By:	 	/s/ Clive Bode
		 	Name: Clive Bode
		 	Title:   Vice President
	
	TPG BIOTECHNOLOGY PARTNERS IV L.P.
		
	By:	 	TPG Biotechnology GenPar IV, L.P.,
its general partner
		
	By:	 	TPG Biotech GenPar IV Advisors,
LLC, its general partner
		
	By:	 	/s/ Clive Bode
		 	Name: Clive Bode
		 	Title:   Vice President

 [Signature Page to Amendment Agreement]EX-10.2

 Exhibit 10.2 

DIRECTOR CONFIDENTIALITY AGREEMENT 

THIS DIRECTOR CONFIDENTIALITY AGREEMENT (this “Agreement”) is entered into as of May 5, 2016 and is effective
upon the date hereof, by and between Endo International plc, a public limited company incorporated under the laws of Ireland (“Endo”), Todd B. Sisitsky, an individual (“Sisitsky”), and TPG Global, LLC
(“TPG” or, either Sisitsky or TPG, a “receiving party”). 
 WHEREAS, concurrently with the
execution of this Agreement, Sisitsky is being appointed to serve on the Board of Directors of Endo; and 
 WHEREAS, in connection
with Sisitsky’s appointment, the parties may disclose to each other certain non-public confidential and proprietary information pertaining to such possible relationship, as set forth below. 

NOW THEREFORE, the parties hereto, intending to be legally bound, agree as follows: 

 

	1.	For purposes of this Agreement, “Confidential Information” shall mean all non-public and proprietary information that has been or will be disclosed by one party, or one of its Affiliates to the other party, or
one of its Affiliates, whether set forth orally or in writing which may relate to among other things, their respective business interests, technical information, clinical data, product specifications, product development plans and ideas, marketing
plans and ideas, manufacturing information, financial information, strategic considerations or business operations. Endo Confidential Information may also include non-public and proprietary information of its Affiliates. 

For purposes of this Agreement, “Affiliate” means with respect to a particular party, a person, corporation or partnership or other
entity that controls, is controlled by or under common control with such party. For the purposes of this definition, “control” (including the correlative meaning, the terms “controlled by” or “under common control
with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by ownership of fifty percent (50%) or more of the
voting stock of such entity, or by contract or otherwise. 
  

	2.	The parties hereby agree that the following shall not be considered Confidential Information subject to this Agreement: 

  

	 	(a)	information that, prior to the time of disclosure, is in the public domain; 

  

	 	(b)	information that, after disclosure, becomes part of the public domain by publication or otherwise; provided that such publication is not in violation of this Agreement or, to the receiving party’s knowledge, any
other confidentiality agreement to which Sisitsky, TPG or any of their respective Affiliates is party; 

 Director Confidentiality Agreement 

 

	 	(c)	information that the receiving party can establish in writing was already known to it or was in its possession prior to the time of disclosure and was not acquired, directly or indirectly, from the disclosing party;

  

	 	(d)	information that the receiving party lawfully received from a third party; provided however, that such third party was not obligated to hold such information in confidence; 

 

	 	(e)	information that was independently developed by the receiving party without reference to any Confidential Information as established by appropriate documentation; and 

 

	 	(f)	information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction; provided, however, that in such case the receiving party shall immediately give as much advance
notice as feasible to the disclosing party so that the disclosing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that,
in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court or tribunal. 

 

	3.	Subject to paragraph 4, the receiving party and the TPG Recipients (as defined below) shall not use Confidential Information of the disclosing party for any purpose other than for the purpose of Sisitsky’s service
as a director of Endo; provided, however, that Sisitsky and the TPG Recipients (as defined below) shall be entitled, subject to compliance with applicable law, to use Confidential Information for purposes of monitoring, managing and
making investment, voting, governance or other decisions relating to TPG’s and its Affiliates’ investment in Endo. 

  

	4.	The receiving party will not disclose any such Confidential Information to any person; provided, however, that Confidential Information may be disclosed by Sisitsky or any TPG Recipient to (i) in the
case of Confidential Information that is financial performance information regarding the Company, any employees, attorneys, independent contractors designated as senior advisors, directors and officers of TPG or its Affiliates (excluding portfolio
companies) (the “TPG Recipients”) and (ii) in all cases, to TPG Recipients who serve on the investment committee of TPG Capital or to any partners, employees and senior advisors of TPG or any of its Affiliates that need to know
such information for the purposes set forth in paragraph 3, in the case of each of clauses (i) and (ii) so long as such TPG Recipients have relevant knowledge or expertise and are bound by confidentiality obligations at least as
restrictive as those contained in this Agreement. TPG represents and warrants that it has instituted reasonable procedures to ensure compliance with the foregoing restrictions on disclosures to TPG Recipients and agrees that it will reasonably
cooperate with Endo to institute further procedures that are necessary or appropriate to protect Confidential Information of Endo. 

  
 2 

 Director Confidentiality Agreement 

 

	5.	Upon written request of the disclosing party, the receiving party shall return promptly to the disclosing party (or, at the receiving party’s option, destroy) all Confidential Information furnished to it, including
any copies thereof and notes, extracts, or derivative materials based thereon (provided that if the receiving party so opts to destroy, the receiving party shall confirm and certify such destruction in writing to the disclosing party); and until
this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies or other
documents which reflect any of the Confidential Information. Notwithstanding the foregoing provision, the receiving party shall not be required to delete the Confidential Information from back-up archival storage and may retain one (1) copy of
Confidential Information in its confidential files solely for record keeping and compliance purposes. 

  

	6.	Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under this Agreement shall remain vested in the disclosing party or any of its Affiliates. Nothing herein shall be
construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copyright and/or any other rights now or hereafter held by the disclosing party or any Affiliate of the disclosing party
in or as a result of such Confidential Information other than as specifically agreed upon by the parties. 

  

	7.	Each receiving party acknowledges that, by virtue of the examination of the Confidential Information in accordance with the terms of this Agreement, it and its Affiliates, employees, attorneys, independent contractors
designated as senior advisors, directors and officers may have access to material, non-public information, and it is aware (and will so advise its Affiliates, employees, attorneys, independent contractors designated as senior advisors, directors and
officers who are informed as to the matters which are subject to this Agreement and who receive Confidential Information) that applicable securities laws, including United States federal and state securities laws, generally prohibit any person who
has material, non-public information concerning a publicly-traded company from purchasing or selling any securities of such company or from communicating such information to any other person or entity under circumstances in which it is reasonably
foreseeable that such person is likely to purchase or sell such securities. Each receiving party agrees that it will not, and will direct its Affiliates, employees, attorneys, independent contractors designated as senior advisors, directors and
officers who have received Confidential Information not to, use or permit any third party to use any Confidential Information in contravention of the United States federal and state securities laws, including the Securities Exchange Act of 1934, as
amended, including the rules and regulations promulgated thereunder. 

  

	8.	The execution and performance of this Agreement does not obligate the parties, or any of the parties’ Affiliates, to enter into any other agreement or to perform any obligations other than as specified herein.

  
 3 

 Director Confidentiality Agreement 

 

	9.	The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party may cause irreparable harm to the disclosing party or its
Affiliates, and that any breach or threatened breach of this Agreement by the receiving party will entitle the disclosing party or any of its Affiliates to seek injunctive relief, in addition to any other legal remedies available to it, in any court
of competent jurisdiction. 

  

	10.	No failure or delay by the disclosing party or any of its Affiliates in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude
any other or future exercise thereof or the exercise of any other right, power or privilege hereunder. 

  

	11.	The parties hereby agree that this Agreement represents the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and/or contemporaneous agreements and understandings
between the parties with respect to the handling of Confidential Information (including the Confidentiality Agreement by and among Endo Pharmaceuticals, Inc., Sisitsky and TPG, dated April 25, 2016), whether written, oral, visual, audio or in
any other medium whatsoever. This Agreement shall be governed by the laws of the Commonwealth of Pennsylvania without reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument
signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the unenforceable provision shall be deemed modified to the limited
extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein. 

  

	12.	This Agreement shall terminate and all obligations and rights hereunder shall expire upon the first anniversary of the first date on which Sisitsky is no longer a member of the board of directors of Endo.

  

	13.	This Agreement shall be binding on each party’s successors and assigns. 

  

	14.	This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute the same agreement. Signatures to this Agreement transmitted by facsimile, by
electronic mail in “portable document format” (“.pdf”), or by any other electronic means which preserves the original graphic and pictorial appearance of the Agreement, shall have the same effect as physical delivery of the paper
document bearing the original signature. 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first
above written. 
  

									
	ENDO INTERNATIONAL PLC	 		 	
					
	By:	 	/s/ Rajiv De Silva	 		 	By:	 	/s/ Todd B. Sisitsky
	Name:	 	Rajiv De Silva	 		 		 	Todd B. Sisitsky
	Title:	 	President and CEO	 		 		 	
			
	TPG GLOBAL, LLC	 		 	
					
	By:	 	/s/ Clive Bode	 		 		 	
	Name:	 	Clive Bode	 		 		 	
	Title:	 	Vice President	 		 		 	

 [Signature Page to Director Confidentiality Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]